Invalid Symbol

Stock Research for EXEL

EXEL
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

EXEL Stock Chart & Research Data

The EXEL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EXEL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EXEL Due diligence Resources & Stock Charts

The EXEL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EXEL Detailed Price Forecast - CNN Money CNN View EXEL Detailed Summary - Google Finance
Yahoo View EXEL Detailed Summary - Yahoo! Finance Zacks View EXEL Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View EXEL Trends & Analysis - Trade-Ideas Barrons View EXEL Major Holders - Barrons
NASDAQ View EXEL Call Transcripts - NASDAQ Seeking View EXEL Breaking News & Analysis - Seeking Alpha
Spotlight View EXEL Annual Report - CompanySpotlight.com OTC Report View EXEL OTC Short Report - OTCShortReport.com
TradeKing View EXEL Fundamentals - TradeKing Charts View EXEL SEC Filings - Bar Chart
WSJ View Historical Prices for EXEL - The WSJ Morningstar View Performance/Total Return for EXEL - Morningstar
MarketWatch View the Analyst Estimates for EXEL - MarketWatch CNBC View the Earnings History for EXEL - CNBC
StockMarketWatch View the EXEL Earnings - StockMarketWatch MacroAxis View EXEL Buy or Sell Recommendations - MacroAxis
Bullish View the EXEL Bullish Patterns - American Bulls Short Pains View EXEL Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View EXEL Stock Mentions - StockTwits PennyStocks View EXEL Stock Mentions - PennyStockTweets
Twitter View EXEL Stock Mentions - Twitter Invest Hub View EXEL Investment Forum News - Investor Hub
Yahoo View EXEL Stock Mentions - Yahoo! Message Board Seeking Alpha View EXEL Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for EXEL - SECform4.com Insider Cow View Insider Transactions for EXEL - Insider Cow
CNBC View EXEL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EXEL - OTC Markets
Yahoo View Insider Transactions for EXEL - Yahoo! Finance NASDAQ View Institutional Holdings for EXEL - NASDAQ


Stock Charts

FinViz View EXEL Stock Insight & Charts - FinViz.com StockCharts View EXEL Investment Charts - StockCharts.com
BarChart View EXEL Stock Overview & Charts - BarChart Trading View View EXEL User Generated Charts - Trading View


Latest Financial News for EXEL

AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Posted on Monday February 19, 2018

AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.


Celgene Reports Positive Data on Dermatology Drug Otezla
Posted on Monday February 19, 2018

Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.


Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
Posted on Friday February 16, 2018

Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.


Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Posted on Friday February 16, 2018

Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.


The case for Bristol-Myers Squibb
Motley Fool - Feb 16, 2018
Bristol-Myers Squibb has more arrows in its quiver than Exelixis does. The stock also looks less expensive, with a forward earnings multiple half as large as Exelixis'. And there's the solid dividend that BMS offers, whereas Exelixis doesn't pay a ...

Decision Time: Exelixis Inc (NASDAQ:EXEL) Stock Technicals Hit Inflection Point
CML News - 8 hours ago
Decision Time: Exelixis Inc (NASDAQ:EXEL) now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point.

Alps Advisors Inc. Has $635000 Position in Exelixis, Inc. (NASDAQ:EXEL)
StockNewsTimes - 10 hours ago
Exelixis logo Alps Advisors Inc. cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 91.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
Sigma Planning Corp Acquires Shares of 6840 Exelixis, Inc. (EXEL) - The Ledger Gazette
SG Americas Securities LLC Has $1.29 Million Holdings in Exelixis, Inc ... - The Lincolnian Online

Is It Time to go for Textron Inc. (TXT), Exelixis, Inc. (EXEL)?
StockNewsJournal - Feb 16, 2018
Exelixis, Inc. (NASDAQ:EXEL) ended its day at 29.78 with the rising stream of 0.81% and its total traded volume was 1.85 million shares less than the average volume.

Enter a stock symbol to view the stock details.